Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by Jesus4Prezon Nov 26, 2020 11:20am

839 Views

Post# 31978694

Orphan Indication PAH

It is my understanding that drugs being tested in the clinic for Orphan indications can potentially receive commercialization approval straight out of Phase 2. Does anyone have more knowledge about this? It seems funny that the current Phase 2 PAH Orphan indication study is so under the radar. Could this rarely mentioned Phase 2 which is currently ongoing become our catalyst? That would ironic, but a very welcome outcome.

J4P

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project